July 14, 2020

The Niche

Knoepfler lab stem cell blog

Robert Lanza

1 min read

Here is a link to the Ocata website, marking the start of a new era for what was formerly Advanced Cell Technology or ACT. It’s been a big summer for stem cell biotech Advanced Cell Technology (ACT; stock ACTCD) as it continues what I would call a process of reinventing itself. What’s been happening? ACT recently did a notable 100:1 reverse split on its stock, opening it up to a whole new group of investors. The company has also settled some previously lingering litigation and …Read More

1 min read

I was challenged to do the Ice Bucket Challenge by Roman Reed. I did it yesterday and can see it was mighty cold! Total shock, but fun. It sure wakes you up. Yeah, we have a drought but I did the big splash with tons of ice. I did the challenge in honor of patients with ALS and the ALS Foundation, patients with Spinal Muscle Atrophy (SMA) and the Gwendolyn Strong Foundation, and the St. Baldrick’s Foundation for children’s cancer research. I’ve already given …Read More

6 min read

Advanced Cell Technology (ACT; $ACTC) has a new paper out on using human embryonic stem cells (hESC) to make MSCs with potentially powerful therapeutic potential. The paper, entitled Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties, was published in the journal Stem Cells and Development. What’s the scoop on this paper and this area of adult stem cell preclinical/clinical research? It’s an interesting, notable paper. At the same time there are some areas in the paper that could have been …Read More